<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081623</url>
  </required_header>
  <id_info>
    <org_study_id>ROSS Gen 2</org_study_id>
    <nct_id>NCT04081623</nct_id>
  </id_info>
  <brief_title>Trans-abdominal Fetal Pulse Oximetry: Signal Integrity</brief_title>
  <official_title>Trans-abdominal Fetal Pulse Oximetry: Signal Integrity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raydiant Oximetry, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raydiant Oximetry, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is set up to advance and integrate the established mathematical principles of
      oxygen saturation to model with increasing accuracy the &quot;body in a body&quot; problem of fetus in
      mother; similar to existing pulse oximeters,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational device is a non-invasive fetal pulse oximeter that measures fetal
      arterial pulse signal using safe, noninvasive, transabdominal near-infrared spectroscopy. The
      optical sensor will obtain fetal pulse oximetry signals. Women will also undergo sonographic
      evaluation to assess distance from maternal skin to fetal tissue and to confirm fetal
      presentation and position. There is no change to standard of care procedures for fetal heart
      rate monitoring. The fetal heart rate that will be monitored with the investigational device
      will be used for research purposes only. Results will not be used to guide or alter patient
      management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal signal integrity</measure>
    <time_frame>During NST, BPP, or active labor</time_frame>
    <description>Integrity of the fetal signal relative to background maternal signal and biologic/electronic noise, and related to fetal position, presentation and the depth of the fetus from maternal skin.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fetal Distress</condition>
  <arm_group>
    <arm_group_label>Clinic</arm_group_label>
    <description>This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labor and Delivery</arm_group_label>
    <description>This group is in active labor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Raydiant Oximetry Sensing System</intervention_name>
    <description>The investigational device is used to record fetal pulse signals.</description>
    <arm_group_label>Clinic</arm_group_label>
    <arm_group_label>Labor and Delivery</arm_group_label>
    <other_name>ROSS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing their scheduled visit to the MFM clinic for a NST/BPP or in latent labor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women with singleton pregnancies, vertex presentation

          2. Age ≥ 18 years

          3. Healthy women ≥ 28 weeks gestation undergoing either Non-Stress test (NST) or
             Biophysical profile (BPP) OR

          4. Healthy women ≥ 37 weeks in labor

          5. Vertex presentation

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Multiple gestation ( twins, triplets)

          3. Presentation other than vertex

          4. &lt; 28 weeks of gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Kemp, MA, BS</last_name>
    <phone>650-822-7762</phone>
    <email>laurakemp@raydiantoximetry.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Russ Delonzor, BSM</last_name>
    <phone>650-822-7762</phone>
    <email>russdelonzor@raydiantoximetry.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidya Iyer, MBBS,CCRP</last_name>
      <phone>617-636-0186</phone>
      <email>viyer1@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Errol R Norwitz, MD, PhD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Distress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

